FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |
|-------------|------------|
| | |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| l | OMB APPRO | VAL | | | | |
|---|------------------------|-----------|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | |
| l | Estimated average burd | en | | | | |
| l | hours per response: | 0.5 | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Braunstein Scott | | | | | 2. Issuer Name and Ticker or Trading Symbol ArTara Therapeutics, Inc. [TARA] | | | | | | | | | Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | |
|---|---|--|---|---|---|------|-----------|-----------------------------|---|--------|--------------------|---|-----------------|---|---|--|---|---|---------------------------------------|--|
| (Last) (First) (Middle) C/O ARTARA THERAPEUTICS, INC. 1 LITTLE WEST 12TH STREET (Street) NEW YORK NY 10014 | | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/09/2020 | | | | | | | | | | Officer (give title below) | | Other (s below) | | specify | | |
| | | | | 4. 1 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | Form f | (Check Ap orting Person One Repo | n | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | Persor | | e triai | Tone Repo | rung | | | |
| | | Tak | ole I - Noi | n-Deri | vative | e Se | ecurities | s Ac | quired, | Dis | posed o | f, or E | enef | icially | Owned | | | | | |
| | | Date | 2. Transaction Date (Month/Day/Year | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Code (| Transaction Code (Instr. | | | |) or 4 and | | es ally Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | Code | v | Amount | _ | or F | Price | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | | |
| Common Stock | | | 01/1 | /10/2020 | | | | A | | 26,500 |)(1) | 4 | \$0.00 | 26,500 | | D | | | | |
| | | • | Table II - | | | | | | uired, D , optior | | | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution I if any (Month/Day | Date, y/Year) | 4. Transaction Code (Instr 8) | | | | 6. Date Exercisable an Expiration Date (Month/Day/Year) | | | 7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4 | | | B. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4) | e s lly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | or Nu of | mber ares | | | | | | |
| Stock Option (Right to Buy) | \$9.18 | 01/09/2020 ⁽²⁾ | | | A | | 9,537 | | (3) | C | 05/24/2028 | Commo Stock | n 9, | 537 | (4) | 9,537 | , | D | | |
| Stock Option (Right to Buy) | \$9.18 | 01/09/2020 ⁽²⁾ | | | A | | 2,861 | | (5) | C | 07/11/2028 | Commo Stock | n 2, | 861 | (6) | 2,861 | | D | | |
| Stock Option (Right to Buy) | \$9.18 | 01/09/2020 ⁽²⁾ | | | A | | 9,537 | | (7) | 1 | 2/31/2028 | Commo Stock | n 9, | 537 | (4) | 9,537 | , | D | | |
| Stock Option (Right to Buy) | \$9.18 | 01/09/2020 ⁽²⁾ | | | A | | 6,676 | | (7) | 1 | 2/31/2028 | Commo Stock | ⁿ 6, | 676 | (8) | 6,676 | | D | | |
| Stock Option (Right to | \$9.18 | 01/09/2020 ⁽²⁾ | | | A | | 15,737 | | (9) | 0 | 14/28/2029 | Commo | n 15 | ,737 | (10) | 15,73 | 7 | D | | |

Explanation of Responses:

- 1. The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full.
- 2. On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer.
- 3. 1/48th of the shares subject to the option shall vest monthly following June 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer.
- 4. Received in the Merger in exchange for a stock option to acquire 50,000 shares of ArTara Sub common stock for \$1.75 per share.
- 5. 1/48th of the shares subject to the option shall vest monthly following August 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer.
- 6. Received in the Merger in exchange for a stock option to acquire 15,000 shares of ArTara Sub common stock for \$1.75 per share.
- 7. 1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer.
- 8. Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for \$1.75 per share.
- 9. 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer.
- 10. Received in the Merger in exchange for a stock option to acquire 82,500 shares of ArTara Sub common stock for \$1.75 per share.

Remarks:

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.